Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: A randomized trial with fluvastatin

Hypertension

Volumn 47, Issue 6, 2006, Pages 1125-1130

  Van Der Linde, Nicole A J ^a   Sijbrands, Eric J G ^a   Boomsma, Frans ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin; Blood pressure; Cholesterol; Hypercholesterolemia; Lipoproteins; Statins

Indexed keywords

ANGIOTENSIN II; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORADRENALIN; PLACEBO; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HORMONE SENSITIVITY; HUMAN; INFUSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; DRUG ADMINISTRATION; DRUG EFFECT; HYPERCHOLESTEROLEMIA; PATHOPHYSIOLOGY;

ADULT; ANGIOTENSIN II; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; NOREPINEPHRINE; VASOCONSTRICTOR AGENTS;

EID: 33744978145     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000221223.23028.f1     Document Type: Article

References (34)

1. Fuentes R, Uusitalo T, Puska P, Tuomilehto J. Blood cholesterol levels and prevalence of hypercholesterolemia in developing countries: a review of population-based studies carried out from 1979 to 2002. Eur J Cardiovasc Prev Rehabil. 2003;10:411-419.
2. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1995;334:1649-1654.
3. Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium. Diverse signals and effects. Hypertension. 2005;45:163-169.
4. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-β 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90:456-461.
5. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
6. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with died-induced hypercholesterolemia. Circulation. 2000;101:1586-1593.
7. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478.
8. Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Scholkens BA, Bohm M. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol. 1997;272:H2701-H2707.
9. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-2134.
10. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol. 1995;75:582-586.
11. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension. 2004;43:255-262.
12. Defesche JC. Familiar Hypercholesterolemia. In: Betterigde J, ed. Lipids and Vascular Disease, vol 6. London, UK: Martin Dunitz; 2000:65-76.
13. Van der Linde NAJ, Boomsma F, van den Meiracker AH. Role of nitric oxide in modulating systemic pressor responses to different vasoconstrictors in man. J Hypertens. 2005;23:1009-1015.
14. Omboni S, Parati G, Frattola A, Mutti E, Di Rienzo M, Castiglioni P, Mancia G. Spectral and sequence analysis of finger blood pressure variability. Comparison with analysis of intra-arterial recordings. Hypertension. 1993;22:26-33.
15. Gizdulich P, Imholz BP, van den Meiracker AH, Parati G, Wesseling KH. Finapres tracking of systolic pressure and baroreflex sensitivity improved by waveform filtering. J Hypertens. 1996;14:243-250.
16. Admiraal PJ, Derkx FH, Danser AH, Pieterman H, Schalekamp MA. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990;15:44-55.
17. van der Hoorn FA, Boomsma F, Man in 't Veld AJ, Schalekamp MA. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr. 1989;487:17-28.
18. Derkx FH, Tan-Tjiong L, Wenting GJ, Boomsma F, Man in 't Veld AJ, Schalekamp MA. Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension. 1983;5:244-256.
19. Goode GK, Heagerty AM. In vitro response of human peripheral small arteries in hypercholesterolemia and effects of therapy. Circulation. 1995;91:2898-2903.
20. Mace PJE, Watson RDS, Skan W, Littler WA. Inhibition of the baroreceptor heart rate reflex by angiotensin II in normal man. Cardiovasc Res. 1985;19:525-527.
21. Reid I. Interactions between angiotensin II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763-E778.
22. Goldsmith SR, Hasking GJ. Effect of a pressor infusion of angiotensin II on sympathetic activity and heart rate in normal humans. Circ Res. 1991;68:263-268.
23. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, Kingwell BA. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39:1020-1025.
24. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Paolo PP, Collatin S, Pahor M. Effect of HMG-CoA Reductase inhibitors on blood pressure with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-1290.
25. Ikeda T, Sakurai J, Nakayama D, Takahashi Y, Matsuo K, Shibuya Y, Gomi T, Moriya H, Kobayashi S. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens. 2004;17:502-506.
26. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. Efficacy and tolerability of lovostatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol. 1993;71:82-87.
27. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002;40:63-73.
28. Ichiki T, Takeda K, Tokunou T, Lino N, Egashira K, Shimokawa H, Hirano K, Kanaide H, Takeshita A. Downregulation of Ang II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A (HMGcoA) reductase inhibitors in vascular smooth muscle cells. Atherioscler Thromb Vasc Biol. 2001;21:1896-1901.
29. Ballantyne CM, Pazzucconi F, Pinto X, Reckless JP, Stein E, McKenney J, Bortolini M, Chiang YT. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001;23:177-192.
30. Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis. 2003;169:283-291.
31. Jansen AC, Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, Roeters van Lennep HW, Sijbrands EJ, Kastelein JJ. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256:482-90.
32. Mazzolai L, Duchosal MA, Korber M, Bouzourene K, Aubert JF, Hao H, Vallet V, Brunner HR, Nussberger J, Gabbiani G, Hayoz D. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a th1 response in ApoE-/- mice. Hypertension. 2004;44:277-282.
33. Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Metha P, Metha JL. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998;18:1433-1439.
34. Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation. 2004;110:1013-1020.